A controlled preclinical study in an animal AD model showing reversal of multiple network and molecular abnormalities with 40 Hz stimulation; sound design but limited to rodents and requires confirmation in humans.
This is a preclinical mechanistic study developing a novel transgenic tracking platform in mice, demonstrating proof-of-concept for labeling degenerating neurons but lacking clinical translation or therapeutic outcome data.
First in vivo characterization of spike-LFP coupling in AD model with single-arm intervention study; mechanistic findings in transgenic mice require confirmation in larger, controlled trials before clinical translation.
An uncontrolled mechanistic study in a transgenic mouse model using human-derived extracellular vesicles as a pooled intervention, with modest neuropathological changes and no primary clinical endpoint, requires confirmation before clinical translation.
Mechanistic study in transgenic mice identifying divergent microglial phenotypes between R47H variant and null mutation; no clinical endpoint or human validation provided.
A systematic review synthesizing methodological approaches and limitations of animal models for multi-infarct dementia, providing guidance on model selection and design rather than reporting novel experimental evidence.
Preclinical study in transgenic mice demonstrating mechanism of a novel compound on hypoxia-accelerated AD pathology, without clinical translation or comparative efficacy data.
Animal model study with in-silico support showing ergosterol reduces oxidative stress and neuroinflammation in STZ-induced rat AD; no human data, mechanistic insight only, and lacks quantified effect sizes with confidence intervals.